Serum S-100 has prognostic significance in malignant melanoma

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2975-2977

  Bonfrer, Johannes M G ^a   Korse, Catharina M ^a   Israels, S Pjotr ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Malignant melanoma; S 100

Indexed keywords

NEURON SPECIFIC ENOLASE; PROTEIN S 100;

CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

HUMANS; MELANOMA; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 0030815172     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Chapter Cytological diagnosis of melanoma. In: Biopsy Pathology of melanocytic disorders (Mooi WS and Krausz T, eds). Chapman-Hall Medical-London, 1993, pp 404-420.
2. Gaynor R, Herschman HR, Irie R, Jones P, Morton D and Cochran A: S-100 protein: a marker for human malignant melanomas? Lancet i: 869-871, 1981.
3. Bates SE: Clinical applications of serum tumor markers. Annals Int Med 115(8): 623-638, 1991.
4. Royds JA et al: Plasma γ enolase as a marker for malignant melanoma. J Pathol 142: A33, 1984.
5. Uerlich M et al: Neuronspezifische enolase und β2-mikroglobulin in serum von melanom patienten. Immun Infekt 16: 65-67, 1988.